Product Description
Fluvoxamine is used to treat obsessive compulsive disorder (OCD). It belongs to a group of medicines known as selective serotonin reuptake inhibitors (SSRIs). These medicines are thought to work by increasing the activity of a chemical called serotonin in the brain.
Mechanisms of Action: SSR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Brazil, China, Netherlands, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: COVID-19|Severe Acute Respiratory Syndrome
Phase 1: Alzheimer Disease|Healthy Volunteers|Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06821698 |
KP-001-106 | P1 |
Completed |
Other |
2025-05-20 |
12% |
2025-09-13 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
CTR20222356 |
CTR20222356 | P1 |
Completed |
Alzheimer Disease |
2023-03-13 |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT04727424 |
TOGETHER_2 | P3 |
Recruiting |
Severe Acute Respiratory Syndrome|COVID-19 |
2024-06-01 |
44% |
2024-05-09 |
|
NCT06232109 |
ASN51-104 | P1 |
Completed |
Healthy Volunteers|Alzheimer Disease |
2024-07-03 |
12% |
2024-12-19 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05888207 |
D5084C00015 | P1 |
Completed |
Healthy Volunteers |
2023-08-17 |
23% |
2023-08-30 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |